Cargando…

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

OBJECTIVES: To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). PATIENTS AND METHODS: This was a 10-week (8-week active treatment/2-week post-treatment) randomized, double-blind, pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gang, McIntyre, Alexander, Earley, Willie R, Raines, Shane R, Eriksson, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916085/
https://www.ncbi.nlm.nih.gov/pubmed/24511235
http://dx.doi.org/10.2147/NDT.S50248
_version_ 1782302663976681472
author Wang, Gang
McIntyre, Alexander
Earley, Willie R
Raines, Shane R
Eriksson, Hans
author_facet Wang, Gang
McIntyre, Alexander
Earley, Willie R
Raines, Shane R
Eriksson, Hans
author_sort Wang, Gang
collection PubMed
description OBJECTIVES: To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). PATIENTS AND METHODS: This was a 10-week (8-week active treatment/2-week post-treatment) randomized, double-blind, placebo- and active-controlled study (D1448C00004). Patients received quetiapine XR 150 mg/day, escitalopram 10 mg/day, or placebo; patients with an inadequate response (<20% improvement in Montgomery–Åsberg Depression Rating Scale [MADRS] total score) at week two received double-dose treatment. The primary end point was week eight change from randomization in MADRS total score. Secondary end points included MADRS response (≥50% improvement) and remission (score ≤8); Hamilton Rating Scale for Depression total and item 1; Hamilton Rating Scale for Anxiety total, psychic, and somatic; Clinical Global Impressions – Severity of Illness total; Pittsburgh Sleep Quality Index (PSQI) global; and Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form percentage maximum total scores. Tolerability was assessed throughout. RESULTS: A total of 471 patients was randomized. No significant improvements in MADRS total score were observed at week eight (last observation carried forward) with either active treatment (quetiapine XR, −17.21 [P=0.174]; escitalopram, −16.73 [P=0.346]) versus placebo (−15.61). There were no significant differences in secondary end points versus placebo, with the exception of week-eight change in PSQI global score (quetiapine XR, −4.96 [P<0.01] versus placebo, −3.37). Mixed-model repeated-measures analysis of observed-case data suggested that the primary analysis may not be robust. Most commonly reported adverse events included dry mouth, somnolence, and dizziness for quetiapine XR, and headache and nausea for escitalopram. CONCLUSION: In this study, neither quetiapine XR (150/300 mg/day) nor escitalopram (10/20 mg/day) showed significant separation from placebo. Both compounds have been shown previously to be effective in the treatment of MDD; possible reasons for this failed study are discussed. Quetiapine XR was generally well tolerated, with a profile similar to that reported previously.
format Online
Article
Text
id pubmed-3916085
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39160852014-02-07 A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder Wang, Gang McIntyre, Alexander Earley, Willie R Raines, Shane R Eriksson, Hans Neuropsychiatr Dis Treat Original Research OBJECTIVES: To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). PATIENTS AND METHODS: This was a 10-week (8-week active treatment/2-week post-treatment) randomized, double-blind, placebo- and active-controlled study (D1448C00004). Patients received quetiapine XR 150 mg/day, escitalopram 10 mg/day, or placebo; patients with an inadequate response (<20% improvement in Montgomery–Åsberg Depression Rating Scale [MADRS] total score) at week two received double-dose treatment. The primary end point was week eight change from randomization in MADRS total score. Secondary end points included MADRS response (≥50% improvement) and remission (score ≤8); Hamilton Rating Scale for Depression total and item 1; Hamilton Rating Scale for Anxiety total, psychic, and somatic; Clinical Global Impressions – Severity of Illness total; Pittsburgh Sleep Quality Index (PSQI) global; and Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form percentage maximum total scores. Tolerability was assessed throughout. RESULTS: A total of 471 patients was randomized. No significant improvements in MADRS total score were observed at week eight (last observation carried forward) with either active treatment (quetiapine XR, −17.21 [P=0.174]; escitalopram, −16.73 [P=0.346]) versus placebo (−15.61). There were no significant differences in secondary end points versus placebo, with the exception of week-eight change in PSQI global score (quetiapine XR, −4.96 [P<0.01] versus placebo, −3.37). Mixed-model repeated-measures analysis of observed-case data suggested that the primary analysis may not be robust. Most commonly reported adverse events included dry mouth, somnolence, and dizziness for quetiapine XR, and headache and nausea for escitalopram. CONCLUSION: In this study, neither quetiapine XR (150/300 mg/day) nor escitalopram (10/20 mg/day) showed significant separation from placebo. Both compounds have been shown previously to be effective in the treatment of MDD; possible reasons for this failed study are discussed. Quetiapine XR was generally well tolerated, with a profile similar to that reported previously. Dove Medical Press 2014-01-30 /pmc/articles/PMC3916085/ /pubmed/24511235 http://dx.doi.org/10.2147/NDT.S50248 Text en © 2014 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wang, Gang
McIntyre, Alexander
Earley, Willie R
Raines, Shane R
Eriksson, Hans
A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
title A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
title_full A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
title_fullStr A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
title_full_unstemmed A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
title_short A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
title_sort randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine xr) monotherapy in patients with major depressive disorder
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916085/
https://www.ncbi.nlm.nih.gov/pubmed/24511235
http://dx.doi.org/10.2147/NDT.S50248
work_keys_str_mv AT wanggang arandomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT mcintyrealexander arandomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT earleywillier arandomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT rainesshaner arandomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT erikssonhans arandomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT wanggang randomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT mcintyrealexander randomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT earleywillier randomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT rainesshaner randomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder
AT erikssonhans randomizeddoubleblindstudyoftheefficacyandtolerabilityofextendedreleasequetiapinefumaratequetiapinexrmonotherapyinpatientswithmajordepressivedisorder